ORMP - Oramed Genomma Lab joint venture to commercialize oral COVID vaccine in Mexico

Oramed Pharmaceuticals (NASDAQ:ORMP) and Genomma Lab Internacional (OTCPK:GNMLF) have formed a 50/50 joint venture to commercialize Oramed's oral COVID-19 vaccine candidate in Mexico. Genomma will provide resources to the vaccine's development, as well as clinical, regulatory, and commercial activities in Mexico. The two companies will also enter into a $20M share swap. The Oramed candidate targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, which the companies say may make it more effective against current and future variants. Oramed received clearance last month to begin a phase 1 trial of the oral vaccine in South Africa.

For further details see:

Oramed, Genomma Lab joint venture to commercialize oral COVID vaccine in Mexico